



April 20, 2020

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051

Scrip code: 532531

Scrip code: STAR

Dear Madam/ Sir,

Subject: Press Release

Please find attached Press Release issued by the Company titled:

“Strides receives USFDA approval for Flucytosine Capsules”

Thanking you,

Yours faithfully,
For **Strides Pharma Science Limited**

A handwritten signature in blue ink that reads 'Manjula R.'.

Manjula Ramamurthy
Company Secretary



Encl. As above

Strides Pharma Science Limited
(Formerly Strides Shasun Limited)
CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India
Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India
Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

info@strides.com; www.strides.com

Strides receives USFDA approval for Flucytosine Capsules

Product approval from flagship facility in Bangalore

To be marketed by Strides Pharma Inc. in the US market

Bangalore, April 20, 2020 - Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for **Flucytosine Capsules USP, 250 mg and 500 mg** from the United States Food & Drug Administration (USFDA). The product is a generic version of Ancobon® Capsules, 250 mg and 500 mg, of Bausch Health US, LLC.

According to IQVIA MAT data, the US market for Flucytosine Capsules USP, 250 mg and 500 mg is approximately US\$ 45 Mn. The product will be manufactured at the company's flagship facility at Bangalore and will be marketed by Strides Pharma Inc. in the US market.

The company has 123 cumulative ANDA filings with USFDA of which 86 ANDAs have been approved and 37 are pending approval.

About Flucytosine Capsules

Flucytosine Capsule is indicated only in the treatment of serious infections caused by susceptible strains of *Candida* (septicemia, endocarditis and urinary system infections) and/or *Cryptococcus* (meningitis and pulmonary infections).

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India- Bangalore (two locations), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and United States-Florida. The Company focusses on "difficult to manufacture" products that are sold in over 100 countries. Additional information is available at the Company's website at www.strides.com

For further information, please contact:

<p>Strides Badree Komandur Executive Director - Finance +91 80 6784 0747</p>	<p>PR Consultancy Fortuna PR K Srinivas Reddy: +91 90005 27213 srinivas@fortunapr.com</p>
--	--

Investor Relations

Kannan. N: +91 98450 54745

Vikesh Kumar: +91 80 6784 0827

Sandeep Baid: +91 80 6784 0791

Email: Sandeep.baid@strides.com

Strides Pharma Science Limited

(Formerly Strides Shasun Limited)

CIN: L24230MH1990PLC057062

Regd. Office: 201, 'Devavrata', Sector - 17,
Vashi, Navi Mumbai - 400 703

Corp. Office: Strides House, Bannerghatta
Road, Bangalore – 560 076

K Priya: +91 95354 25418

priya@fortunapr.com